Ignite Creation Date:
2025-12-25 @ 1:33 AM
Ignite Modification Date:
2025-12-25 @ 11:47 PM
Study NCT ID:
NCT07245394
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-11-24
First Post:
2025-09-17
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)
Sponsor:
TIDHI Innovation Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-12-01
Start Date Type:
ESTIMATED
Primary Completion Date:
2027-11-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-11-01
Completion Date Type:
ESTIMATED
First Submit Date:
2025-09-17
First Submit QC Date:
None
Study First Post Date:
2025-11-24
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-17
Last Update Post Date:
2025-11-24
Last Update Post Date Type:
ESTIMATED